Baricitinib Effectiveness in JAKi-Naïve and Tofacitinib-Exposed Patients: A Prospective Study in Alopecia Areata

This prospective study evaluated the effectiveness and safety of baricitinib in 44 patients with severe alopecia areata (AA), divided into JAK inhibitor (JAKi)-naïve patients and those previously treated with tofacitinib. The study found that JAKi-naïve patients experienced significant improvement in their Severity of Alopecia Tool (SALT) scores after 12 months of baricitinib treatment, while tofacitinib-exposed patients did not show statistically significant changes. The safety profile of baricitinib was favorable, with no significant adverse events leading to treatment discontinuation. The study suggests that initial treatment with baricitinib may be more effective for JAKi-naïve patients and highlights the need for biomarkers to predict individual responses to JAKi therapy. Further research is needed to confirm these findings and optimize treatment strategies for AA.